![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/en/news-release/2024/07/09/2910304/0/en/VYNE-Therapeutics-Announces-Appointment-of-Subhashis-Banerjee-M-D-as-Senior-Vice-President-of-Clinical-Development.html
https://www.globenewswire.com/news-release/2024/06/26/2904448/0/en/VYNE-Therapeutics-to-Participate-in-Leerink-Partners-Therapeutics-Forum.html
https://www.globenewswire.com/news-release/2024/06/13/2898338/0/en/VYNE-Therapeutics-Announces-Dosing-of-First-Participants-in-Phase-1a-Trial-of-Novel-BD2-Selective-BET-Inhibitor-VYN202.html
https://www.globenewswire.com/news-release/2024/06/05/2893807/0/en/VYNE-Therapeutics-Announces-Dosing-of-First-Subject-in-Phase-2b-Vitiligo-Trial-of-Novel-BET-Inhibitor-VYN201.html
https://www.globenewswire.com/news-release/2024/05/09/2878712/0/en/VYNE-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/05/06/2875779/0/en/VYNE-Therapeutics-Announces-FDA-Clearance-of-IND-Application-for-VYN202-a-Novel-BD2-Selective-BET-Inhibitor.html
https://www.globenewswire.com/news-release/2024/05/01/2873158/0/en/VYNE-Therapeutics-Announces-Oral-Presentations-for-VYN201-at-the-2024-Society-for-Investigative-Dermatology-SID-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/03/19/2848504/0/en/VYNE-Therapeutics-to-Participate-in-the-H-C-Wainwright-2nd-Annual-Autoimmune-Inflammatory-Disease-Virtual-Conference.html
https://www.globenewswire.com//news-release/2024/02/29/2837916/0/en/VYNE-Reports-2023-Fourth-Quarter-and-Year-End-Financial-Results-and-Provides-Business-Update.html